Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2009 (2009), Article ID 616054, 12 pages
Clinical Study

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function

1Department of Gastroenterology CA-2121, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
2Department of Medicine CA-2121, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
3Department of Anesthesia, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
4Department of Biomedical Sciences, The Panum Institute, Nørre Alle 20, DK-2200 Copenhagen, Denmark
5Department of Clinical Physiology and Nuclear Medicin, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Received 24 March 2009; Revised 22 June 2009; Accepted 25 June 2009

Academic Editor: Karel Geboes

Copyright © 2009 P. B. Jeppesen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background and aims. In a short-term study, Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients. This study describes longitudinal changes in relation to GLP-2 treatment for two years. Methods. GLP-2, 400 micrograms, s.c.,TID, were offered, to eleven SBS patients keeping parenteral support constant. 72-hour nutritional balance studies were performed at baseline, weeks 13, 26, 52 during two years intermitted by an 8-week washout period. In addition, mucosal morphometrics, renal function (by creatinine clearance), body composition and bone mineral density (by DEXA), biochemical markers of bone turnover (by s-CTX and osteocalcin, PTH and vitamin D), and muscle function (NMR, lungfunction, exercise test) were measured. Results. GLP-2 compliance was > 93%. Three of eleven patients did not complete the study. In the remaining 8 patients, GLP-2 significantly reduced the fecal wet weight from approximately 3.0 to approximately 2.0 kg/day. This was accompanied by a decline in the oral wet weight intake, maintaining intestinal wet weight absorption and urinary weight constant. Renal function improved. No significant changes were demonstrated in energy intake or absorption, and GLP-2 did not significantly affect mucosal morphology, body composition, bone mineral density or muscle function. Conclusions. GLP-2 treatment reduces fecal weight by approximately 1000 g/d and enables SBS patients to maintain their intestinal fluid and electrolyte absorption at lower oral intakes. This was accompanied by a 28% improvement in creatinine clearance.